Related Experiment Videos
Tacrolimus-associated hemolytic uremic syndrome: a case analysis
Chih-Ching Lin1, Kuang-Liang King, Yu-Wen Chao
1Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital and School of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China. lincc2@vghtpe.gov.tw
Journal of Nephrology
|December 31, 2003
Summary
Tacrolimus can cause Hemolytic Uremic Syndrome (HUS) in transplant patients, particularly in females. Early recognition and aggressive management are crucial to reduce mortality and graft loss.
Area of Science:
- Nephrology
- Immunology
- Transplantation Medicine
Background:
- Tacrolimus is a vital immunosuppressant for organ transplantation.
- Hemolytic Uremic Syndrome (HUS) is a serious, albeit rare, complication associated with tacrolimus use.
Observation:
- This study analyzes 16 cases of tacrolimus-associated HUS, revealing a higher prevalence in females (56.3%) with a mean age of onset at 41.3 years.
- Renal transplant recipients constituted 44% of cases, with HUS onset occurring an average of 7.1 months after the initial tacrolimus dose.
- Treatment strategies included anticoagulation, antiplatelet therapy, tacrolimus dose modification, switching to cyclosporine, plasma exchange, and dialysis, with varying success rates.
Findings:
- Mortality risk factors in transplant recipients with tacrolimus-associated HUS were identified as non-renal transplantation, lower peak serum creatinine, liver dysfunction, and elevated lactate dehydrogenase (LDH) levels.
- While 43.7% of patients experienced improved graft function, 31.3% died and 25% lost their graft despite interventions.
- Tacrolimus trough levels did not correlate with patient prognosis.
Implications:
- HUS must be considered in the differential diagnosis of declining renal function in patients receiving tacrolimus post-transplantation.
- Vigilant renal function monitoring and prompt, aggressive treatment are essential to mitigate morbidity and mortality.
- Identifying and managing patients with specific risk factors can improve outcomes in tacrolimus-associated HUS.